ZIM
NBIX icon

Zacks Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Zacks Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
+20,271
New +$3.01M 0.02% 302
2023
Q2 		– Sell
-51,176
Closed -$5.18M – 696
2023
Q1 		$5.18M Buy
51,176
+1,712
+3% +$178K 0.07% 187
2022
Q4 		$5.91M Buy
49,464
+1,091
+2% +$128K 0.08% 178
2022
Q3 		$5.14M Buy
+48,373
New +$4.91M 0.08% 171
2015
Q4 		– Sell
-7,969
Closed -$317K – 627
2015
Q3 		$317K Buy
+7,969
New +$385K 0.01% 500
2014
Q1 		– Sell
-27,084
Closed -$253K – 741
2013
Q4 		$253K Buy
+27,084
New +$264K 0.01% 602

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zacks Investment Management's NBIX Position: Q2 2026 in Review

Zacks Investment Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 20,271 shares worth $3.42M. The stake represents 0.02% of the portfolio and ranks #302 among its holdings. This is a return to the name: Zacks Investment Management previously reported a position in NBIX as recently as Q1 2023.

Zacks Investment Management first reported a position in NBIX in Q4 2013 and has held it in 6 quarters since. The position peaked at $5.91M in Q4 2022. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Zacks Investment Management held 20,271 shares of Neurocrine Biosciences worth $3.42M as of Q2 2026.
  • Neurocrine Biosciences was a new Zacks Investment Management position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Zacks Investment Management's portfolio in Q2 2026, its #302 holding.
  • Zacks Investment Management first reported a position in Neurocrine Biosciences in Q4 2013 and has held it in 6 quarters since.
  • Zacks Investment Management's Neurocrine Biosciences position peaked at $5.91M in Q4 2022.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.